List of works - Sima Rafati Seyedi Yazdi

A Synthetic Peptide 2Abz23S29 Reduces Bacterial Titer and Induces Pro-Inflammatory Cytokines in a Murine Model of Urinary Tract Infection

scientific article published on 17 July 2020

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.

scientific article

A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis

scientific article published on 13 July 2017

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

scientific article

Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.

scientific article

Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials

scientific article published on 27 February 2019

Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy

scientific article published on 25 March 2016

Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites

scientific article published on 14 July 2017

Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.

scientific article published on 21 July 2017

Biological delivery approaches for gene therapy: Strategies to potentiate efficacy and enhance specificity ⬇️

scientific article published on August 1, 2013

Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: A Case Study.

scientific article published on 27 August 2015

C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice ⬇️

scientific article published on July 12, 2011

CD8(+) T cells in leishmania infections: friends or foes?

scientific article published on 24 January 2012

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

scientific article published in December 2013

Chemokine-based immunotherapy: delivery systems and combination therapies.

scientific article published on August 2012

Comparing acute and chronic human cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica focusing on arginase activity

scientific article published on 21 July 2016

Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice

scientific article

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice

scientific article published on 25 January 2006

Computational evaluation of modified peptides from human neutrophil peptide 1 (HNP-1)

scientific article published on 26 September 2020

Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice

scientific article published on 31 October 2009

Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection

article

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

scientific article published on 01 June 2011

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

scientific article

DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening

scientific article published in January 2016

DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica

scientific article published on 11 January 2019

Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection

scientific article published on 19 April 2011

Delivery systems for Leishmania vaccine development

scientific article published on 24 February 2016

Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis ⬇️

scientific article published on April 18, 2013

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model

scientific article published on 17 October 2012

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica.

scientific article published on 9 November 2015

EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.

scientific article published on 19 December 2015

Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae

scientific article published on 26 March 2011

Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

scientific article published on 18 April 2008

Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model

scientific article published on 23 May 2016

Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen

scientific article (publication date: March 2014)

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.

scientific article

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis

scientific article published on 25 December 2010

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

scientific article

Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis

scientific article published in March 2003

Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies

scientific article published on 25 December 2010

Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity

scientific article published on 28 January 2015

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice

scientific article published on 18 December 2017

Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate

scientific article (publication date: 2013)

Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population

scientific article published in January 2004

IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis

scientific article published on 11 February 2015

Identification of Leishmania major cysteine proteinases as targets of the immune response in humans

scientific article published in March 2001

Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells.

scientific article

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

scientific article published in November 2003

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies

scientific article published in November 2011

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

scientific article published in May 2004

Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7

article

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine

scientific article

Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice

article

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

scientific article

Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

scientific article published on 25 August 2012

Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen

scientific article published on 18 May 2015

Improvement of different vaccine delivery systems for cancer therapy ⬇️

scientific article published on January 7, 2011

In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein

scientific article

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

scientific article

In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications

scientific article published on 8 December 2009

In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

scientific article

Innate immune system: Specific or non-specific?

scientific article published on 07 May 2007

Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

scientific article

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

scientific article

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model

scientific article published on 26 January 2011

Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity

scientific article published on 22 April 2010

Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against L. major-infected BALB/c mice

scientific article published on 18 August 2017

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model

scientific article published on 19 August 2015

Leishmania-based expression systems.

scientific article

Leishmaniasis and various immunotherapeutic approaches.

scientific article published on 15 December 2016

Leishmaniasis: Middle East and North Africa research and development priorities

scientific article (publication date: July 2011)

Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

scientific article published on January 2012

Live vaccination tactics: possible approaches for controlling visceral leishmaniasis

scientific article

Mammalian host defense peptides and their implication on combating Leishmania infection

scientific article

Mini-chaperones: potential immuno-stimulators in vaccine design

scientific article

Old World cutaneous leishmaniasis challenges in Morocco, Algeria, Tunisia and Iran (MATI): a collaborative attempt to combat the disease

scientific article published on 31 March 2017

PUF Proteins: Cellular Functions and Potential Applications.

scientific article published on 14 September 2016

Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice.

scientific article published on January 2009

Post-Genomics and Vaccine Improvement for Leishmania

scientific article

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

scientific article published on 16 November 2005

Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control

scientific article published on 12 June 2018

Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy

scientific article published on 3 March 2006

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

scientific article published in May 2005

Protein/Protein, DNA/DNA and DNA/Protein based vaccination strategies using truncated Omp2b against Brucella infection in BALB/c Mice.

scientific article published on 28 March 2017

Recombinant Leishmania major lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway

scientific article published on 16 July 2015

Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.

scientific article published on November 2012

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

scientific article published on 8 October 2009

Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation

scientific article

Retracted: Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis

retracted article

Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae.

scientific article published on 6 May 2009

Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.

scientific article

T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania major Lipophosphoglycan 3.

scientific article

Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis

scientific article

The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women

article

The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

scientific article

The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropica

scientific article published on 07 January 2020

The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene

scientific article published in November 2008

The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis

scientific article published on 01 December 1999

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin

scientific article published on 22 August 2018

Transcriptomic profiling in Cutaneous Leishmaniasis patients

scientific article published on 04 September 2020

Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis

scientific article published on May 2004

Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice.

scientific article published on 24 February 2015

List of works by Sima Rafati Seyedi Yazdi

A Synthetic Peptide 2Abz23S29 Reduces Bacterial Titer and Induces Pro-Inflammatory Cytokines in a Murine Model of Urinary Tract Infection

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.

A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.

Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials

Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy

Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites

Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.

Biological delivery approaches for gene therapy: Strategies to potentiate efficacy and enhance specificity ⬇️

Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: A Case Study.

C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice ⬇️

CD8(+) T cells in leishmania infections: friends or foes?

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

Chemokine-based immunotherapy: delivery systems and combination therapies.

Comparing acute and chronic human cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica focusing on arginase activity

Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice

Computational evaluation of modified peptides from human neutrophil peptide 1 (HNP-1)

Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice

Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening

DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica

Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection

Delivery systems for Leishmania vaccine development

Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis ⬇️

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica.

EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.

Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae

Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model

Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis

Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies

Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice

Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate

Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population

IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis

Identification of Leishmania major cysteine proteinases as targets of the immune response in humans

Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells.

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine

Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen

Improvement of different vaccine delivery systems for cancer therapy ⬇️

In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications

In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Innate immune system: Specific or non-specific?

Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model

Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity

Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against L. major-infected BALB/c mice

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model

Leishmania-based expression systems.

Leishmaniasis and various immunotherapeutic approaches.

Leishmaniasis: Middle East and North Africa research and development priorities

Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

Live vaccination tactics: possible approaches for controlling visceral leishmaniasis

Mammalian host defense peptides and their implication on combating Leishmania infection

Mini-chaperones: potential immuno-stimulators in vaccine design

Old World cutaneous leishmaniasis challenges in Morocco, Algeria, Tunisia and Iran (MATI): a collaborative attempt to combat the disease

PUF Proteins: Cellular Functions and Potential Applications.

Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice.

Post-Genomics and Vaccine Improvement for Leishmania